Management of Immunotherapy-Related Toxicities, Version 1.2022

John A. Thompson; Bryan J. Schneider; Julie Brahmer; Amaka Achufusi; Philippe Armand; Meghan K. Berkenstock; Shailender Bhatia; Lihua E. Budde; Saurin Chokshi; Marianne Davies; Amro Elshoury; Yaron Gesthalter; Aparna Hegde; Michael Jain; Benjamin H. Kaffenberger; Melissa G. Lechner; Tianhong Li; Alissa Marr; Suzanne McGettigan; Jordan McPherson; Theresa Medina; Nisha A. Mohindra; Anthony J. Olszanski; Olalekan Oluwole; Sandip P. Patel; Pradnya Patil; Sunil Reddy; Mabel Ryder; Bianca Santomasso; Scott Shofer; Jeffrey A. Sosman; Yinghong Wang; Vlad G. Zaha; Megan Lyons; Mary Dwyer; Lisa Hang

doi:10.6004/jnccn.2022.0020

Management of Immunotherapy-Related Toxicities, Version 1.2022

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Amaka Achufusi, Philippe Armand, Meghan K. Berkenstock, Shailender Bhatia, Lihua E. Budde, Saurin Chokshi, Marianne Davies, Amro Elshoury, Yaron Gesthalter, Aparna Hegde, Michael Jain, Benjamin H. Kaffenberger, Melissa G. Lechner, Tianhong Li, Alissa Marr, Suzanne McGettigan, Jordan McPhersonTheresa Medina, Nisha A. Mohindra, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Pradnya Patil, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Vlad G. Zaha, Megan Lyons, Mary Dwyer, Lisa Hang

Research output: Contribution to journal › Article › peer-review

138 Scopus citations

Abstract

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.

Original language	English (US)
Pages (from-to)	387-405
Number of pages	19
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	4
DOIs	https://doi.org/10.6004/jnccn.2022.0020
State	Published - Apr 2022

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2022.0020

Cite this

Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M., Elshoury, A., Gesthalter, Y., Hegde, A., Jain, M., Kaffenberger, B. H., Lechner, M. G., Li, T., Marr, A., McGettigan, S., ... Hang, L. (2022). Management of Immunotherapy-Related Toxicities, Version 1.2022. JNCCN Journal of the National Comprehensive Cancer Network, 20(4), 387-405. https://doi.org/10.6004/jnccn.2022.0020

Thompson, JA, Schneider, BJ, Brahmer, J, Achufusi, A, Armand, P, Berkenstock, MK, Bhatia, S, Budde, LE, Chokshi, S, Davies, M, Elshoury, A, Gesthalter, Y, Hegde, A, Jain, M, Kaffenberger, BH, Lechner, MG, Li, T, Marr, A, McGettigan, S, McPherson, J, Medina, T, Mohindra, NA, Olszanski, AJ, Oluwole, O, Patel, SP, Patil, P, Reddy, S, Ryder, M, Santomasso, B, Shofer, S, Sosman, JA, Wang, Y, Zaha, VG, Lyons, M, Dwyer, M & Hang, L 2022, 'Management of Immunotherapy-Related Toxicities, Version 1.2022', JNCCN Journal of the National Comprehensive Cancer Network, vol. 20, no. 4, pp. 387-405. https://doi.org/10.6004/jnccn.2022.0020

@article{fd936d70c20b453ba13629ae573bcc38,

title = "Management of Immunotherapy-Related Toxicities, Version 1.2022",

abstract = "The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.",

author = "Thompson, {John A.} and Schneider, {Bryan J.} and Julie Brahmer and Amaka Achufusi and Philippe Armand and Berkenstock, {Meghan K.} and Shailender Bhatia and Budde, {Lihua E.} and Saurin Chokshi and Marianne Davies and Amro Elshoury and Yaron Gesthalter and Aparna Hegde and Michael Jain and Kaffenberger, {Benjamin H.} and Lechner, {Melissa G.} and Tianhong Li and Alissa Marr and Suzanne McGettigan and Jordan McPherson and Theresa Medina and Mohindra, {Nisha A.} and Olszanski, {Anthony J.} and Olalekan Oluwole and Patel, {Sandip P.} and Pradnya Patil and Sunil Reddy and Mabel Ryder and Bianca Santomasso and Scott Shofer and Sosman, {Jeffrey A.} and Yinghong Wang and Zaha, {Vlad G.} and Megan Lyons and Mary Dwyer and Lisa Hang",

year = "2022",

month = apr,

doi = "10.6004/jnccn.2022.0020",

language = "English (US)",

volume = "20",

pages = "387--405",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "4",

}

TY - JOUR

T1 - Management of Immunotherapy-Related Toxicities, Version 1.2022

AU - Thompson, John A.

AU - Schneider, Bryan J.

AU - Brahmer, Julie

AU - Achufusi, Amaka

AU - Armand, Philippe

AU - Berkenstock, Meghan K.

AU - Bhatia, Shailender

AU - Budde, Lihua E.

AU - Chokshi, Saurin

AU - Davies, Marianne

AU - Elshoury, Amro

AU - Gesthalter, Yaron

AU - Hegde, Aparna

AU - Jain, Michael

AU - Kaffenberger, Benjamin H.

AU - Lechner, Melissa G.

AU - Li, Tianhong

AU - Marr, Alissa

AU - McGettigan, Suzanne

AU - McPherson, Jordan

AU - Medina, Theresa

AU - Mohindra, Nisha A.

AU - Olszanski, Anthony J.

AU - Oluwole, Olalekan

AU - Patel, Sandip P.

AU - Patil, Pradnya

AU - Reddy, Sunil

AU - Ryder, Mabel

AU - Santomasso, Bianca

AU - Shofer, Scott

AU - Sosman, Jeffrey A.

AU - Wang, Yinghong

AU - Zaha, Vlad G.

AU - Lyons, Megan

AU - Dwyer, Mary

AU - Hang, Lisa

PY - 2022/4

Y1 - 2022/4

N2 - The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.

AB - The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.

UR - http://www.scopus.com/inward/record.url?scp=85129042015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129042015&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2022.0020

DO - 10.6004/jnccn.2022.0020

M3 - Article

C2 - 35390769

AN - SCOPUS:85129042015

SN - 1540-1405

VL - 20

SP - 387

EP - 405

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 4

ER -

Management of Immunotherapy-Related Toxicities, Version 1.2022

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this